We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Simple DNA Test Could Identify the Risk of Inherited Diseases

By HospiMedica International staff writers
Posted on 04 Mar 2010
An inexpensive, fast, and accurate test using a drop of saliva pinpoints variations at critical points along the DNA chain. More...


Researchers from the University of Edinburgh (UK) developed the new method, which is based on dynamic chemical analysis, and delivers reliable results without the need for the expensive enzymes used in conventional DNA testing. The new method allows the analysis of single-nucleotide polymorphism, indel, and abasic sites using mass spectrometry as a readout tool. Differences or omissions in the DNA code could then show if someone is healthy, susceptible to disease, or is suffering from a serious medical condition.

Currently, the test can look for genetic variations for only one disease at a time, but the researchers hope the technique could be used eventually to decode the whole human genome, which would give information about genetic variations across the whole spectrum of disease. The test takes about 30 minutes, and the methodology is suitable for the dual analysis of heterozygous samples. The study describing the new technique was published in the February 2010 issue of the journal Angewandte Chemie.

"What we have developed is a way of testing chemically; that means not using enzymes, which are the current method,” said lead author Juan Diaz-Mochon, Ph.D., of the school of chemistry. "The technology offers a speedy, cost-efficient alternative to existing methods of DNA analysis.”

"The test could help spot diseases, such as pancreatic cancer, early. It could also indicate if someone had a risk of other diseases, such as heart problems or dementia,” added coauthor Prof. Mark Bradley, Ph.D. "We plan to test the technology further, extend our collaborations with leading researchers and companies in the DNA sequencing field, and establish our first commercial operations within the next six months.”

Related Links:

University of Edinburgh



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.